Last updated: February 25, 2026
What is NDC 70677-1228?
NDC 70677-1228 corresponds to Darbepoetin alfa (marketed as Aranesp), a synthetic erythropoietin used to treat anemia associated with chronic kidney disease, chemotherapy, or bone marrow transplantation. It is produced by Amgen.
Current Market Dynamics
Market Size and Growth
- The global erythropoiesis-stimulating agent (ESA) market, including darbepoetin alfa, was valued at approximately $6.5 billion in 2022.
- The CAGR from 2022 to 2027 is expected to reach 7.5%, driven by increasing prevalence of anemia in chronic conditions and expanding indications.
Key Market Segments
| Segment |
Share (2022) |
Growth Drivers |
| Chronic Kidney Disease (CKD) |
55% |
Rising CKD prevalence, improved detection, aging population |
| Chemotherapy-Induced Anemia |
25% |
Growing cancer incidence, improved supportive care protocols |
| Bone Marrow Transplantation |
10% |
Advances in hematological therapies, increasing transplant procedures |
| Others |
10% |
Off-label uses, experimental indications |
Competitive Landscape
- Major players: Amgen, Roche (via Esbriet), Janssen (via Retacrit/Basgeron)
- Amgen dominates with approximately 60% market share.
- Biosimilars are gaining ground in EU markets, with biosimilar darbepoetin alfa approved in Europe since 2017.
Price Trends and Projections
Current Pricing Overview
| Region |
Average Cost per Dose |
Source |
Date |
| U.S. |
$480 - $600 |
Medicare, Private Insurers |
2023 |
| EU |
€350 - €460 |
European hospitals |
2023 |
Factors Influencing Price
- Patent expiry of the original biologic in some regions (e.g., 2024 for U.S. patent expiration).
- Entry of biosimilars reduces prices by 20-40% per dose.
- Hospital purchasing agreements influence negotiated prices, often lower than list prices.
Price Projection (2023-2028)
| Year |
Estimated Average Cost per Dose |
Notes |
| 2023 |
$560 |
Stable, with ongoing biosimilar competition |
| 2024 |
$460 |
Biosimilar entry expected, with discounts of around 20-25% on original biologic |
| 2025 |
$440 |
Increased biosimilar adoption, price erosion accelerates |
| 2026 |
$420 |
Market saturation of biosimilars, further price reductions |
| 2027 |
$410 |
Stabilization around 10-15% below original price |
Key Price Drivers
- Biosimilar market penetration
- Patent expirations and exclusivity periods
- Regulatory policies and payer negotiations
- Manufacturing costs and supply chain dynamics
Future Market Opportunities and Risks
Opportunities
- Expanding use in anemia management for patients with heart failure
- Oncologic indications expanding with clinical trials
- Emerging markets with rising healthcare infrastructure
Risks
- Entry of novel anemia therapies (e.g., HIF-PH inhibitors)
- Regulatory hurdles and reimbursement policies
- Market saturation in developed markets
Summary
The darbepoetin alfa market, represented by NDC 70677-1228, will experience gradual price decreases due to biosimilar competition. Price erosion is projected to be approximately 15-20% over five years, with a significant drop following biosimilar approvals. Growth in global markets and new indications offsets some competitive pressures.
Key Takeaways
- The market for darbepoetin alfa is nearing patent expiry in key regions, amid rising biosimilar competition.
- Prices are expected to decline substantially in the next five years, with a 10-15% decrease post-biosimilar entry.
- The total market size continues to grow, driven by aging populations and expanded indications.
- Biosimilar adoption will catalyze price reductions, but brand-name biologics maintain market share through clinical familiarity.
- Regulatory and reimbursement policies will significantly influence pricing strategies and market penetration.
FAQs
1. When does the patent for the original darbepoetin alfa biologic expire?
The patent in the U.S. is expected to expire in 2024, opening pathways for biosimilar entry.
2. How will biosimilar entry impact prices?
Biosimilar entry typically reduces prices by 20-40%, accelerating market share shifts from the originator.
3. What are the main indications for darbepoetin alfa?
Chronic kidney disease-associated anemia, chemotherapy-induced anemia, and supportive care in transplantation.
4. Which regions will see the highest price decline?
European markets are likely to experience faster biosimilar adoption and price reductions, followed by North America.
5. What are the risks to future price stability?
Regulatory barriers, slow biosimilar adoption due to physician or payer hesitancy, and the emergence of alternative therapies pose risks.
References
- Grand View Research. (2022). Erythropoiesis-Stimulating Agents Market Size, Share & Trends Analysis Report.
- IQVIA. (2023). Global Biologic Pricing Trends Report.
- European Medicines Agency. (2017). Biosimilar medicines.
- U.S. Food and Drug Administration. (2022). Biosimilar and Interchangeable Products.
- Smith, J. A., & Lee, R. M. (2021). The evolving landscape of erythropoiesis-stimulating agents. Journal of Hematology, 15(3), 123-132.
